Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

Sources

Coverage

Limited spectrum

Sentiment

0.00

◀ Left 100%Centre 0%Right 0% ▶

How we rate bias →

This story is currently only covered by one source from a single part of the political spectrum. NewsDeck will update this page automatically if other outlets pick up the story.

shopping_bagPolitical Documentaries

Documentary box sets covering elections, Westminster, and modern British political history.

Browse documentaries on Amazonarrow_forward

NewsDeck Poll

Do you think this story is being covered fairly across the political spectrum?

Loading…

Left

(1)

Guardian Business

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionis…